The spectrum and incidence of BRCA1 pathogenic mutations in Slovak breast/ovarian cancer families

Neoplasma

Volumn 54, Issue 2, 2007, Pages 137-142

  Konecny, M ^a   Vizvaryova, M ^a   Weismanova, E ^a   Ilencikova, D ^b   Mlkva, I ^c   Weismann, P ^d   Machackova, G ^d   Kausitz, J ^a  

^a ST ELIZABETH CANCER INSTITUTE   (Slovakia)

^b National Oncology Institute   (Slovakia)

^c FACULTY HOSPITAL   (Slovakia)

^d Physics and Informatics   (Slovakia)

Author keywords

BRCA1; Breast cancer; Mutation analysis; Ovarian cancer; Slovak population

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CODING; FAMILY HISTORY; FEMALE; FRAME SHIFT MUTATION; GENE MUTATION; GENE SEQUENCE; GENETIC IDENTIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NOMENCLATURE; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; ONCOGENE; OVARY CANCER; PATHOGENESIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SLOVAKIA; BLOOD; BREAST TUMOR; FRAMESHIFT MUTATION; GENE AMPLIFICATION; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; OVARY TUMOR; PATHOLOGY; PILOT STUDY; POLYMERASE CHAIN REACTION; RISK FACTOR; STOP CODON; TUMOR SUPPRESSOR GENE;

DNA; RNA;

AGED; BREAST NEOPLASMS; CODON, NONSENSE; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FRAMESHIFT MUTATION; GENE AMPLIFICATION; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PILOT PROJECTS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RISK FACTORS; RNA, NEOPLASM; SLOVAKIA;

EID: 34347238627     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. NEWMAN B, AUSTIN MA, LEE M, KING MC. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci USA 1988; 85: 3044-3048.
2. MARTIN AM, BLACKWOOD MA, ANTIN-OZERKIS D, SHIH HA, CALZONE K, COLLIGON TA, SEAL S, COLLINS N, STRATTON MR, WEBER BL, NATHANSON KL. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. J Clin Oncol 2001; 19: 2247-2253.
3. ANTONIOU AC, DUROCHER F, SMITH P, SIMARD J, INHERITED BRCAs program members, Easton DF. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res 2006; 8: R3 (doi:10.1186/bcr1365).
4. Breast Cancer Information Core Database (http://research.nhgri.nih.gov/ bic/).
5. The Human Gene Mutation Database (http://www.hgmd.cf.ac.uk/ac/index.php).
6. LLORT G, MUNOZ CY, TUSER MP, GUILLERMO IB, LLUCH JR, BALE AE, FRANCO MA. Low frequency of recurrent BRCA1 and BRCA2 mutations in Spain. Hum Mutat 2002; 19: 307.
7. NEUHAUSEN SL. Ethnic differences in cancer risk resulting from genetic variation. Cancer 1999; 86: 2575-2582. (Pubitemid 30007541)
8. THORLACIUS S, OLAFSDOTTIR G, TRYGGVADOTTIR L, NEUHAUSEN S, JONASSON JG, TAVTIGIAN SV, TULINIUS H, OGMUNDSDOTTIR HM, EYFJORD JE. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996; 13: 117-119.
9. ROA BB, BOYD AA, VOLCIK K, RICHARDS CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996; 14: 185-187. (Pubitemid 26338801)
10. FRIEDMAN LS, OSTERMEYER EA, SZABO CI, DOWD P, LYNCH ED, ROWELL SE, KING MC. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994; 8: 399-404.
11. CLAES K, MACHACKOVA E, DE VOS M, MORTIER G, DE PAEPE A, MESSIAEN L. Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 flemish families with breast and/or ovarian cancer but not in 12 sporadic patients with early-onset disease. Hum Mutat 1999; 13: 256.
12. ANTONARAKIS SE, Nomenclature Working Group. Recommendations for a nomenclature system for human gene mutations. Hum Mutat 1998; 11: 1-3. (Pubitemid 128679142)
13. DEN DUNNEN JT, ANTONARAKIS SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000; 15: 7-12.
14. DEN DUNNEN JT, PAALMAN MH. Standardizing mutation nomenclature: why bother? Hum Mutat 2003; 22: 181-182.
15. WAGNER TM, MOSLINGER RA, MUHR D, LANGBAUER G, HIRTENLEHNER K, CONCIN H, DOELLER W, HAID A, LANG AH, MAYER P, ROPP E, KUBISTA E, AMIRIMANI B, HELBICH T, BECHERER A, SCHEINER O, BREITENEDER H, BORG A, DEVILEE P, OEFNER P, ZIELINSKI C. BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics. Int J Cancer 1998; 77: 354-360.
16. CIERNIKOVA S, TOMKA M, SEDLAKOVA O, REINEROVA M, STEVURKOVA V, KOVAC M, CENTE M, ILENCIKOVA D, BELLA V, ZAJAC V. The novel exon 11 mutation of BRCA1 gene in a high-risk family. Neoplasma 2003; 50: 403-407.
17. CASTILLA LH, COUCH FJ, ERDOS MR, HOSKINS KF, CALZONE K, GARBER JE, BOYD J, LUBIN MB, DESHANO ML, BRODY LC, et al. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet 1994; 8: 387-391.
18. SYRJAKOSKI K, VAHTERISTO P, EEROLA H, TAMMINEN A, KIVINUMMI K, SARANTAUS L, HOLLI K, BLOMQVIST C, KALLIONIEMI OP, KAINU T, NEVANLINNA H. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 2000; 92: 1529-1531.
19. VEHMANEN P, FRIEDMAN LS, EEROLA H, MCCLURE M, WARD B, SARANTAUS L, KAINU T, SYRJAKOSKI K, PYRHONEN S, KALLIONIEMI OP, MUHONEN T, LUCE M, FRANK TS, NEVANLINNA H. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet 1997; 6: 2309-2315.
20. LADOPOULOU A, KROUPIS C, KONSTANTOPOULOU I, IOANNIDOU-MOUZAKA L, SCHOFIELD AC, PANTAZIDIS A, ARMAOU S, TSIAGAS I, LIANIDOU E, EFSTATHIOU E, TSIONOU C, PANOPOULOS C, MIHALATOS M, NASIOULAS G, SKARLOS D, HAITES NE, FOUNTZILAS G, PANDIS N, YANNOUKAKOS D. Germline BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed. Cancer Lett 2002; 185: 61-70.
21. FORETOVA L, MACHACKOVA E, NAVRATILOVA M, PAVLU H, HRUBA M, LUKESOVA M, VALIK D. BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic. Hum Mutat 2004; 23: 397-398.
22. PERKOWSKA M, BROZEK I, WYSOCKA B, HARALDSSON K, SANDBERG T, JOHANSSON U, SELLBERG G, BORG A, LIMON J. BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland. Hum Mutat 2003; 2: 553-554.
23. PLESKO I, ONDRUSOVA M, STEFANAKOVA D, KUZMA I, HLAVATA B, RAKOCZOVA E, KOMPAUEROVA H, BENESOVA A, MADZOVA J, ONDROVICOVA M, POKRIVCAKOVA M. Cancer incidence in Slovakia 2002. Bratislava: Department of healthcare informations and statistics, 2005.
24. POHLREICH P, ZIKAN M, STRIBRNA J, KLEIBL Z, JANATOVA M, KOTLAS J, ZIDOVSKA J, NOVOTNY J, PETRUZELKA L, SZABO C, MATOUS B. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Res 2005; 7: 728-736
25. MEYER P, VOIGTLAENDER T, BARTRAM CR, KLAES R. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany. Hum Mut 2003; 22: 259.
26. BERGMAN A, FLODIN A, ENGWALL Y, ARKBLAD EL, BERG K, EINBEIGI Z, MARTINSSON T, WAHLSTROM J, KARLSSON P, NORDLING M. A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques. Fam Cancer 2005; 4: 89-96.
27. GAYTHER SA, WARREN W, MAZOYER S, RUSSELL PA, HARRINGTON PA, CHIANO M, SEAL S, HAMOUDI R, VAN RENSBURG EJ, DUNNING AM, LOVE R, EVANS G, EASTON D, CLAYTON D, STRATTON MR, PONDER BA. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet. 1995; 11: 428-433
28. RAMUS SJ, FRIEDMAN LS, GAYTHER SA, PONDER BA, BOBROW L, VAN DER LOOJI M, PAPP J, OLAH E. A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2. Nat Genet. 1997; 15: 14-15
29. STOPPA-LYONNET D, LAURENT-PUIG P, ESSIOUX L, PAGES S, ITHIER G, LIGOT L, FOURQUET A, SALMON RJ, CLOUGH KB, POUILLART P, BONAITI-PELLIE C, THOMAS G. BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet. 1997; 60: 1021-1030
30. SZABO CI, KING MC. Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997; 60: 1013-1020.
31. CSOKAY B, TIHOMIROVA L, STENGREVICS A, SINICKA O, OLAH E. Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia. Hum Mutat 1999; 14: 92.
32. GAYTHER SA, HARRINGTON P, RUSSELL P, KHARKEVICH G, GARKAVTSEVA RF, PONDER BA. Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia. Am J Hum Genet 1997; 60: 1239-1242.
33. VAN DER LOOIJ M, SZABO C, BESZNYAK I, LISZKA G, CSOKAY B, PULAY T, TOTH J, DEVILEE P, KING MC, OLAH E. Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. Int J Cancer 2000; 86: 737-740
34. BACKE J, HOFFERBERT S, SKAWRAN B, DORK T, STUHRMANN M, KARSTENS JH, UNTCH M, MEINDL A, BURGEMEISTER R, CHANG-CLAUDE J, WEBER BH. Frequency of BRCA1 mutation 5382insC in German breast cancer patients. Gynecol Oncol 1999; 72: 402-406.
35. STUPPIA L, DI FULVIO P, ACETO G, PINTOR S, VESCHI S, GATTA V, COLOSIMO A, CIANCHETTI E, CAMA A, MARIANI-COSTANTINI R, BATTISTA P, PALKA G. BRCA1 and BRCA2 mutations in breast/ovarian cancer patients from central Italy. Hum Mutat 2003; 22: 178-179.
36. MANGUOGLU AE, LULECI G, OZCELIK T, COLAK T, SCHAYEK H, AKAYDIN M, FRIEDMAN E. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients. Hum Mutat 2003; 21: 444-445.
37. VEZINA H, DUROCHER F, DUMONT M, HOUDE L, SZABO C, TRANCHANT M, CHIQUETTE J, PLANTE M, LAFRAMBOISE R, LEPINE J, NEVANLINNA H, STOPPALYONNET D, GOLDGAR D, BRIDGE P, SIMARD J. Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families. Hum Genet 2005; 117: 119-132.